Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
Open accessAbstract
Cannabidiol (CBD), a constituent of cannabis with few psychoactive effects, has been reported in some studies to attenuate certain aspects of Δ(9)-tetrahydrocannabinol (THC) intoxication. However, most studies have tested only one dose of CBD in combination with one dose of oral THC, making it difficult to assess the nature of this interaction. Further, the effect of oral CBD on smoked cannabis administration is unknown. The objective of this multi-site, randomized, double-blind, within-subject laboratory study was to assess the influence of CBD (0, 200, 400, 800 mg, p.o.) pretreatment on the reinforcing, subjective, cognitive, and physiological effects of smoked cannabis (0.01 (inactive), 5.30-5.80% THC). Non-treatment-seeking, healthy cannabis smokers (n=31; 17M, 14 F) completed eight outpatient sessions. CBD was administered 90 min prior to cannabis administration. The behavioral and cardiovascular effects of cannabis were measured at baseline and repeatedly throughout the session. A subset of participants (n=8) completed an additional session to measure plasma CBD concentrations after administration of the highest CBD dose (800 mg). Under placebo CBD conditions, active cannabis (1) was self-administered by significantly more participants than placebo cannabis and (2) produced significant, time-dependent increases in ratings of 'High', 'Good Effect', ratings of the cannabis cigarette (eg, strength, liking), and heart rate relative to inactive cannabis. CBD, which alone produced no significant psychoactive or cardiovascular effects, did not significantly alter any of these outcomes. Cannabis self-administration, subjective effects, and cannabis ratings did not vary as a function of CBD dose relative to placebo capsules. These findings suggest that oral CBD does not reduce the reinforcing, physiological, or positive subjective effects of smoked cannabis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CBD alone was unable to reduce self-administration in a human laboratory study and did not alter the subjective and physiological effects of smoked marijuana.
“CBD alone was unable to reduce self-administration in a human laboratory study and did not alter the subjective and physiological effects of smoked marijuana 60.”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [60]
Cites
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Marzo, V. D., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,610 · see citing works
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · see citing works
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · see citing works
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 851 · see citing works
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2× · see citing works
“…(300–600mg) alone has been reported to produce mild sedative and anxiolytic effects in some studies (Zuardi et al, 1993; Crippa et al, 2004, 2011; Bergamaschi et al, 2011a, b), whereas most report no measurable psychoactivity (Benowitz et al, 1980; Borgwardt et al, 2008; Bhattacharyya et al,…”
BackgroundBhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680 · see citing works
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608 · see citing works
Russo, E. B., & Guy, G. W. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 608 · see citing works
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 2× · see citing works
“…(300–600mg) alone has been reported to produce mild sedative and anxiolytic effects in some studies (Zuardi et al, 1993; Crippa et al, 2004, 2011; Bergamaschi et al, 2011a, b), whereas most report no measurable psychoactivity (Benowitz et al, 1980; Borgwardt et al, 2008; Bhattacharyya et al,…”
BackgroundCrippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 511 · see citing works
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465 · see citing works
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J. F., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 462 · see citing works
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406 · see citing works
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364 · see citing works
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303 · see citing works
Effects of Acute Smoked Marijuana on Complex Cognitive Performance
Hart, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00273-1 · Cited by 272 · see citing works
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · see citing works
Self-citationD’Souza, D. C., Ranganathan, M., Braley, G., Gueorguieva, R. V., Zimolo, Z., Cooper, T. B., Perry, E. B., & Krystal, J. H. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301643 · Cited by 263 · see citing works
Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex
Haney, M., Hart, C. L., Vosburg, S. K., Nasser, J. A., Bennett, A., Zúbaran, C., & Foltin, R. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300310 · Cited by 262 · see citing works
Self-citationModulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol
Bhattacharyya, S., Fusar‐Poli, P., Borgwardt, S., Martín‐Santos, R., Nosarti, C., O’Carroll, C., Allen, P., Seal, M. L., Fletcher, P. C., Crippa, J. A. S., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.17 · Cited by 246 · see citing works
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
Niesink, R. J. M., & van Laar, M. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00130 · Cited by 241 · see citing works
Pertwee, R. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.001.0001 · Cited by 232 · see citing works
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152439 · Cited by 231 · see citing works
Potter, D. J., Clark, P., & Brown, M. B. (2008) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2007.00603.x · Cited by 230 · see citing works
Constituents of Cannabis Sativa
ElSohly, M. A., & Gul, W. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0001 · Cited by 227 · see citing works
Cannabidiol in Humans—The Quest for Therapeutic Targets
Zhornitsky, S., & Potvin, S. (2012) · Pharmaceuticals · doi:10.3390/ph5050529 · Cited by 199 · see citing works
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.58 · Cited by 196 · see citing works
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.011 · Cited by 195 · see citing works
Hindocha, C., Freeman, T. P., Schäfer, G., Gardener, C., Das, R., Morgan, C. J. A., & Curran, H. V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.014 · Cited by 183 · see citing works
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids
Ilan, A. B., Gevins, A., Coleman, M., Elsohly, M., & de Wit, H. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00023 · Cited by 169 · see citing works
Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.
Cooper, Z. D., & Haney, M. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00095.x · Cited by 158 · see citing works
Self-citationWinton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Martin-Santos, R., Ffytche, D., Zuardi, A. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.17 · Cited by 146 · see citing works
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129 · see citing works
A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1441-0 · Cited by 128 · see citing works
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123 · see citing works
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.318 · Cited by 117 · cited 2× · see citing works
“…cannabis effects at any point during the 2-h cannabis time course (Figures 1 and 2); note, we did not assess whether CBD altered the metabolism of THC, as there is little to suggest that this occurs in humans (Hunt et al, 1981; Englund et al, 2013; Agurell et al, 1981; Karschner et al, 2011a, b).”
BackgroundResultGrotenhermen, F. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/156800705774322111 · Cited by 112 · see citing works
Schoedel, K. A., Chen, N., Hilliard, A., White, L., Stott, C. G., Russo, E. B., Wright, S., Guy, G. W., Romach, M. K., & Sellers, E. M. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1196 · Cited by 86 · see citing works
(2004) · PsycEXTRA Dataset · doi:10.1037/e437722005-001 · Cited by 74 · see citing works
Wright, M. J., Vandewater, S. A., & Taffe, M. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12199 · Cited by 72 · see citing works
Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction
Benowitz, N. L., Nguyen, T., Jones, R. T., Herning, R. I., & Bachman, J. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.139 · Cited by 67 · see citing works
Juckel, G., Roser, P., Nadulski, T., Stadelmann, A. M., & Gallinat, J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.015 · Cited by 63 · see citing works
Roser, P., Gallinat, J., Weinberg, G., Juckel, G., Gorynia, I., & Stadelmann, A. M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0868-5 · Cited by 54 · see citing works
Effects of smoked marijuana on social interaction in small groups
Foltin, R. W., Brady, J. V., Fischman, M. W., Emurian, C. S., & Dominitz, J. A. (1987) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(87)90079-2 · Cited by 52 · see citing works
Cognition: The ultimate brain function
Robbins, T. W. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.171 · Cited by 50 · see citing works
Hunt, C. A., Jones, R. T., Herning, R. I., & Bachman, J. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059266 · Cited by 50 · see citing works
Towards a better cannabis drug
Mechoulam, R., & Parker, L. A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12400 · Cited by 26 · see citing works
Some physical characteristics of NIDA marijuana cigarettes
Chait, L. D., & Pierri, J. N. (1989) · Addictive Behaviors · doi:10.1016/0306-4603(89)90017-8 · Cited by 26 · see citing works
Does cannabidiol protect against the negative effects of THC?
Henquet, C., & Kuepper, R. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081380 · Cited by 16 · see citing works
Cannabis versus THC: response to Russo and McPartland
ElSohly, M. A., Wachtel, S. R., & de Wit, H. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1349-y · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 567 · see citing works
Review of the Endocannabinoid System
Lu, H., & Mackie, K. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 511 · see citing works
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 381 · see citing works
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307 · see citing works
Self-citationChanging landscape of cannabis: novel products, formulations, and methods of administration
Spindle, T. R., Bonn‐Miller, M. O., & Vandrey, R. G. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.04.002 · Cited by 260 · see citing works
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 236 · see citing works
Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 222 · see citing works
Tasty THC: Promises and Challenges of Cannabis Edibles
RTI International, D., Barrus, D. G., Giombi, K., Cates, S. C., Gourdet, C., Peiper, N. C., Novak, S. P., Lefever, T. W., & Wiley, J. L. (2016) · doi:10.3768/rtipress.2016.op.0035.1611 · Cited by 198 · see citing works
Arkell, T. R., Lintzeris, N., Kevin, R. C., Ramaekers, J. G., Vandrey, R. G., Irwin, C. G., Haber, P., & McGregor, I. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05246-8 · Cited by 182 · see citing works
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181 · see citing works
Lawn, W., Freeman, T. P., Pope, R. A., Joye, A., Harvey, L. A., Hindocha, C., Mokrysz, C., Moss, A., Wall, M. B., Bloomfield, M., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4383-x · Cited by 175 · see citing works
Schoedel, K. A., Szeto, I., Setnik, B., Sellers, E. M., Levy‐Cooperman, N., Mills, C., Etges, T., & Sommerville, K. W. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.07.027 · Cited by 171 · see citing works
Larsen, C., & Shahinas, J. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4090 · Cited by 170 · see citing works
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156 · see citing works
Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 154 · see citing works
Englund, A., Freeman, T. P., Murray, R. M., & McGuire, P. K. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30075-5 · Cited by 151 · see citing works
Kicman, A., & Toczek, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186740 · Cited by 154 · see citing works
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Brezing, C., & LEVIN, F. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.212 · Cited by 144 · see citing works
Drug-induced stress responses and addiction risk and relapse
Wemm, S. E., & Sinha, R. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100148 · Cited by 144 · see citing works
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143 · see citing works
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Babalonis, S. L., Haney, M., Malcolm, R. J., Lofwall, M. R., Votaw, V. R., Sparenborg, S., & WALSH, S. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.030 · Cited by 136 · see citing works
Self-citationElsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 136 · see citing works
Spanagel, R. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/rspanagel · Cited by 127 · see citing works
Spindle, T. R., Cone, E. J., Goffi, E., Weerts, E. M., Mitchell, J. M., Winecker, R. E., Bigelow, G. E., Flegel, R. R., & Vandrey, R. G. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107937 · Cited by 127 · see citing works
Cannabis for Chronic Pain: Challenges and Considerations
Romero-Sandoval, E. A., Fincham, J. E., Kolano, A. L., Sharpe, B. N., & Alvarado-Vazquez, P. A. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2115 · Cited by 128 · see citing works
Trigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J. T., Selby, P. L., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190768 · Cited by 123 · see citing works
Mechanisms Underlying Sex Differences in Cannabis Use
Calakos, K. C., Bhatt, S., Foster, D. W., & Cosgrove, K. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0174-7 · Cited by 121 · see citing works
Russo, C., Ferk, F., Mišík, M., Ropek, N., Nersesyan, A. K., Mejri, D., Holzmann, K., Lavorgna, M., Isidori, M., & Knasmüller, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2322-9 · Cited by 121 · see citing works
Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. S., & Connor, M. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0016 · Cited by 112 · see citing works
“9,10 CBD may modulate D 9 -THC effects at the receptor level acting as a CB 1 negative allosteric modulator, 11 providing some biological plausibility to a modulatory interaction.”
Hindocha, C., Freeman, T. P., Grabski, M., Stroud, J., Crudgington, H., Davies, A. C., Das, R., Lawn, W., Morgan, C. J. A., & Curran, H. V. (2018) · Addiction · doi:10.1111/add.14243 · Cited by 107 · see citing works
Freels, T. G., Baxter-Potter, L. N., Lugo, J. M., Glodosky, N. C., Wright, H. R., Baglot, S. L., Petrie, G. N., Yu, Z., Clowers, B. H., Cuttler, C., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2416-19.2020 · Cited by 105 · see citing works
Deconstructing the neurobiology of cannabis use disorder
Ferland, J.-M. N., & Hurd, Y. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0611-0 · Cited by 81 · see citing works
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96 · see citing works
Englund, A., Oliver, D., Chesney, E., Chester, L. A., Wilson, J., Sovi, S., Micheli, A. D., Hodsoll, J. P., Fusar‐Poli, P., Strang, J., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01478-z · Cited by 96 · see citing works
Zamarripa, C. A., Spindle, T. R., Surujunarain, R., Weerts, E. M., Bansal, S., Unadkat, J. D., Paine, M. F., & Vandrey, R. G. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.54752 · Cited by 96 · see citing works
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
Arnold, J. C., McCartney, D., Suraev, A. S., & McGregor, I. S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13425 · Cited by 90 · see citing works
Cannabidiol does not display drug abuse potential in mice behavior
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Medrano-Relinque, J., Navarrón, C. M., Navarrete, F., & Manzanares, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0032-8 · Cited by 90 · see citing works
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 90 · see citing works
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets
Salami, S. A., Martinelli, F., Giovino, A., Bachari, A., Arad, N., & Mantri, N. L. (2020) · Molecules · doi:10.3390/molecules25184036 · Cited by 86 · see citing works
Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance
Ramaekers, J. G., Mason, N. L., & Theunissen, E. L. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.006 · Cited by 85 · see citing works
Cannabidiol-Δ 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity
Britch, S. C., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.046 · Cited by 83 · see citing works
Wright, M., Ciano, P. D., & Brands, B. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0052 · Cited by 85 · see citing works
Acute effects of cannabinoids on symptoms of obsessive‐compulsive disorder: A human laboratory study
Kayser, R. R., Haney, M., Raskin, M., Arout, C. A., & Simpson, H. B. (2020) · Depression and Anxiety · doi:10.1002/da.23032 · Cited by 85 · see citing works
Self-citationStatement on safety of cannabidiol as a novel food: data gaps and uncertainties
EFSA Panel on Nutrition, N. F. A. F. A. (., Turck, D., Bohn, T., Castenmiller, J. J. M., Henauw, S. D., Hirsch‐Ernst, K. I., Maciuk, A., Mangelsdorf, I., McArdle, H. J., Naska, A., et al. (2022) · EFSA Journal · doi:10.2903/j.efsa.2022.7322 · Cited by 83 · see citing works
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 78 · see citing works
Arout, C. A., Haney, M., Herrmann, E. S., Bedi, G., & Cooper, Z. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14973 · Cited by 69 · see citing works
Self-citationChild, R. B., & Tallon, M. J. (2022) · Nutrients · doi:10.3390/nu14102101 · Cited by 65 · see citing works
Psychoactive constituents of cannabis and their clinical implications: a systematic review
Casajuana, C., López‐Pelayo, H., Balcells‐Oliveró, M., Colom, J., & Gual, A. (2017) · Adicciones · doi:10.20882/adicciones.858 · Cited by 64 · see citing works
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Galaj, E., & Xi, Z. (2019) · CNS Drugs · doi:10.1007/s40263-019-00664-w · Cited by 65 · see citing works
Mongeau‐Pérusse, V., Brissette, S., Bruneau, J., Conrod, P., Dubreucq, S., Gazil, G., Stip, É., & Jutras‐Aswad, D. (2021) · Addiction · doi:10.1111/add.15417 · Cited by 64 · see citing works
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Martin, E. L., Strickland, J. C., Schlienz, N. J., Munson, J., Jackson, H., Bonn‐Miller, M. O., & Vandrey, R. G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.729800 · Cited by 62 · see citing works
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence
Schlag, A. K., Hindocha, C., Zafar, R. R., Nutt, D., & Curran, H. V. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986393 · Cited by 61 · see citing works
Advancing the science on cannabis concentrates and behavioural health
Bidwell, L. C., Martin‐Willett, R., & Karoly, H. C. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13281 · Cited by 60 · see citing works
Casajuana, C., Balcells‐Oliveró, M., López‐Pelayo, H., Miquel, L., Teixidó, L., Colom, J., Nutt, D., Rehm, J. T., & Gual, A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.010 · Cited by 61 · see citing works
A scoping review of the use of cannabidiol in psychiatric disorders
Kirkland, A. E., Fadus, M. C., Gruber, S. A., Gray, K. M., Wilens, T. E., & Squeglia, L. M. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114347 · Cited by 61 · see citing works
Self-citationThe Impact of THC and CBD in Schizophrenia: A Systematic Review
Ahmed, S., Roth, R. M., Stanciu, C. N., & Brunette, M. F. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694394 · Cited by 56 · see citing works
Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults
Arndt, D. L., & de Wit, H. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0014 · Cited by 54 · see citing works
Cogan, P. S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1721281 · Cited by 46 · see citing works
Silmore, L. H., Willmer, A. R., Capparelli, E. V., & Rosania, G. R. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2512 · Cited by 52 · see citing works
Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations
Nia, A. B., Mann, C. L., Kaur, H., & Ranganathan, M. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0167-4 · Cited by 51 · see citing works
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Malinowska, B., Baranowska‐Kuczko, M., Kicman, A., & Schlicker, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041986 · Cited by 50 · see citing works
Strategies to Improve Cannabidiol Bioavailability and Drug Delivery
O’Sullivan, S. E., Jensen, S. S., Kolli, A. R., Nikolajsen, G. N., Bruun, H. Z., & Hoeng, J. (2024) · Pharmaceuticals · doi:10.3390/ph17020244 · Cited by 50 · see citing works
CBD and THC: Do They Complement Each Other Like Yin and Yang?
Pennypacker, S. D., & Romero-Sandoval, E. A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2469 · Cited by 48 · see citing works
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids
Sholler, D. J., Huestis, M. A., Amendolara, B., Vandrey, R. G., & Cooper, Z. D. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173059 · Cited by 48 · see citing works
Self-citationThe Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis
Hahn, B. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx105 · Cited by 47 · see citing works
Craft, S., WINSTOCK, A. R., Ferris, J., Mackie, C. J., Lynskey, M. T., & Freeman, T. P. (2019) · Psychological Medicine · doi:10.1017/s0033291719002460 · Cited by 47 · see citing works
Hobbs, J. M., Vazquez, A. R., Remijan, N. D., Trotter, R. E., Vincent, G. T., Freedman, K. E., Wei, Y., Woelfel, K. A., Arnold, O. R., Wolfe, L. M., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6651 · Cited by 46 · see citing works
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 46 · see citing works
Model‐Based Analysis of Cannabidiol Dose‐Exposure Relationship and Bioavailability
Lim, S. Y., Sharan, S., & Woo, S. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2377 · Cited by 44 · see citing works
Cannabidiol and substance use disorder: Dream or reality
Karimi‐Haghighi, S., Razavi, Y., Iezzi, D., Scheyer, A. F., Manzoni, O. J., & Haghparast, A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108948 · Cited by 45 · see citing works
Andrenyak, D. M., Moody, D. E., Slawson, M. H., OʼLeary, D. S., & Haney, M. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw136 · Cited by 42 · see citing works
Self-citationEffects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
Nona, C. N., Hendershot, C. S., & Foll, B. L. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000272 · Cited by 41 · see citing works
Bidwell, L. C., Mueller, R. L., YorkWilliams, S. L., Hagerty, S. L., Bryan, A. D., & Hutchison, K. E. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0038 · Cited by 40 · see citing works
Bloomfield, M., Green, S. F., Hindocha, C., Yamamori, Y., Yim, J. L., Jones, A., Walker, H. R., Tokarczuk, P. F., Statton, B. K., Howes, O. D., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936419 · Cited by 40 · see citing works
Palmitoylethanolamide: A Potential Alternative to Cannabidiol
Clayton, P., Subah, S., Venkatesh, R., Hill, M., & Bogoda, N. O. (2021) · Journal of Dietary Supplements · doi:10.1080/19390211.2021.2005733 · Cited by 41 · see citing works
Lichenstein, S. D. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00450-7 · Cited by 38 · see citing works
Navarrete, F., Aracil-Fernández, A., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14226 · Cited by 38 · see citing works
Hindocha, C., Freeman, T. P., Grabski, M., Crudgington, H., Davies, A. C., Stroud, J., Das, R. K., Lawn, W., Morgan, C. J. A., & Curran, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-25846-2 · Cited by 37 · see citing works
Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain
Cásedas, G., de Yarza-Sancho, M., & López, V. (2024) · Pharmaceuticals · doi:10.3390/ph17111438 · Cited by 36 · see citing works
Zamarripa, C. A., Vandrey, R. G., & Spindle, T. R. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00429-4 · Cited by 37 · see citing works
Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans
Babalonis, S. L., Lofwall, M. R., Sloan, P. A., Nuzzo, P. A., Fanucchi, L. C., & WALSH, S. L. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05293-1 · Cited by 36 · see citing works
Self-citationCannabis Use and the Endocannabinoid System: A Clinical Perspective
Haney, M. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21111138 · Cited by 35 · see citing works
Self-citationPsychosocial and pharmacological interventions for the treatment of cannabis use disorder
Sabioni, P., & Le Foll, B. (2018) · F1000Research · doi:10.12688/f1000research.11191.1 · Cited by 37 · see citing works
Vadhan, N. P., Corcoran, C. M., Bedi, G., Keilp, J. G., & Haney, M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.070 · Cited by 34 · see citing works
Self-citationEffects of cannabidiol in cannabis flower: Implications for harm reduction
Gibson, L. P., Karoly, H. C., Ellingson, J. M., Klawitter, J., Sempio, C., Squeri, J. E., Bryan, A. D., Bidwell, L. C., & Hutchison, K. E. (2021) · Addiction Biology · doi:10.1111/adb.13092 · Cited by 34 · see citing works
Sagar, K. A., & Gruber, S. A. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13990 · Cited by 33 · see citing works
Translational models of cannabinoid vapor exposure in laboratory animals
Moore, C. F., Stiltner, J. W., Davis, C. M., & Weerts, E. M. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000592 · Cited by 31 · see citing works
Frequent cannabis users demonstrate low knowledge of cannabinoid content and dosages
Kruger, D. J., Kruger, J. S., & Collins, R. L. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1752150 · Cited by 31 · see citing works
Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis
Zadeh, E. M., Chisholm, A., Bachi, K., & Hurd, Y. L. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0025 · Cited by 31 · see citing works
Medications for substance use disorders (SUD): emerging approaches
Butelman, E. R., & Kreek, M. J. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1395855 · Cited by 30 · see citing works
Acute and residual mood and cognitive performance of young adults following smoked cannabis
Matheson, J., Mann, R. E., Sproule, B. A., Huestis, M. A., Wickens, C. M., Stoduto, G., George, T. P., Rehm, J. T., Foll, B. L., & Brands, B. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172937 · Cited by 30 · see citing works
Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol
Greene, N. Z., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5036-z · Cited by 31 · see citing works
Shah, I., Al-Dabbagh, B., Salem, A. E., Hamid, S. A. A., Muhammad, N., & Naughton, D. P. (2019) · BMC Chemistry · doi:10.1186/s13065-019-0627-2 · Cited by 29 · see citing works
Niloy, N., Hediyal, T. A., Vichitra, C., Sharma, S., Chidambaram, S. B., Gorantla, V. R., & Mahalakshmi, A. M. (2023) · Biomolecules · doi:10.3390/biom13010162 · Cited by 28 · see citing works
Spindle, T. R., Zamarripa, C., Russo, E., Pollak, L., Bigelow, G. E., Ward, A. M., Tomspon, B., Sempio, C., Shokati, T., Klawitter, J., et al. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111267 · Cited by 22 · see citing works
Medicinal Cannabis in Orthopaedic Practice
Kleeman-Forsthuber, L. T., Dennis, D. A., & Jennings, J. M. (2019) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-19-00438 · Cited by 28 · see citing works
Dieterle, M., Zurbriggen, L., Mauermann, E., Mercer‐Chalmers‐Bender, K., Frei, P., Ruppen, W., & Schneider, T. (2022) · Pain · doi:10.1097/j.pain.0000000000002591 · Cited by 28 · see citing works
The Relationship Between Circulating Endogenous Cannabinoids and the Effects of Smoked Cannabis
Kearney-Ramos, T. E., Herrmann, E. S., Belluomo, I., Matias, I., Vallée, M., Monlezun, S., Piazza, P. V., & Haney, M. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0185 · Cited by 28 · see citing works
Self-citationRegular cannabis use is associated with blunted affective, but not cardiovascular, stress responses
DeAngelis, B. N., & Al’Absi, M. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106411 · Cited by 26 · see citing works
Molecular Genetics and New Medication Strategies for Opioid Addiction
Hurd, Y. L., & O’Brien, C. P. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030352 · Cited by 24 · see citing works
- Authors
- Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., & Walsh, S. L.
- Affiliations
- Columbia University Irving Medical Center (US)
- Medical University of South Carolina (US)
- University of Kentucky (US)
- National Institute on Drug Abuse (US)
- Corresponding author
- Haney, Margaret
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2015-12-28
- Volume
- 41
- Issue
- 8
- Pages
- 1974-1982
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC4908634
- OpenAlex
- W2221860578
- Cited by
- 206
- References
- 53
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 20 · 2023: 16 · 2022: 29 · 2021: 27 · 2020: 32 · 2019: 18 · 2018: 23 · 2017: 12 · 2016: 6 · 2014: 2
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Supernus Pharmaceuticals
- National Institutes of Health (KL2TR000116, UL1TR000117)
- National Institute on Drug Abuse (U10DA013732, U10DA013727, K23DA034877, P50DA009236, DA009236, UG1DA013732)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- cannabidiol, cannabis smoking, self-administration, subjective effects, cardiovascular effects, heart rate, dose-response relationship
- MeSH terms
- Administration, Oral, Adolescent, Adult, Affect, Cannabidiol, Double-Blind Method, Female, Heart Rate, Humans, Male, Marijuana Smoking, Middle Aged, Reinforcement, Psychology, Self Administration, Dronabinol, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
